<code id='6B4C8520B7'></code><style id='6B4C8520B7'></style>
      • <acronym id='6B4C8520B7'></acronym>
      <center id='6B4C8520B7'><center id='6B4C8520B7'><tfoot id='6B4C8520B7'></tfoot></center><abbr id='6B4C8520B7'><dir id='6B4C8520B7'><tfoot id='6B4C8520B7'></tfoot><noframes id='6B4C8520B7'>
      • <optgroup id='6B4C8520B7'><strike id='6B4C8520B7'><sup id='6B4C8520B7'></sup></strike><code id='6B4C8520B7'></code></optgroup>
        5. <b id='6B4C8520B7'><label id='6B4C8520B7'><select id='6B4C8520B7'><dt id='6B4C8520B7'><span id='6B4C8520B7'></span></dt></select></label></b><u id='6B4C8520B7'></u>
          <i id='6B4C8520B7'><strike id='6B4C8520B7'><tt id='6B4C8520B7'><pre id='6B4C8520B7'></pre></tt></strike></i>
           


   

   

   
   
   
   
   
   
   
   
   
   
   
   
   

   
   
   
   
   
   
   
  
           
  
           
  
           
   
           
    
           
     
           
      
           
       
      
           
      
           
       
           
        
           
         
           
           
          
           
         
           
         
           
           
          
           
         
           
          
        
           
       
           
       
           
        
           
        
           
        
           
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
       
           
       
           
        
           
        
          
          00:00 
        
           
       
           
       
           
      
           
      
           
        
        
        
       
           
        00:00 
         
        00:00 
        LIVE 
       
           
        
       
           
        
           
        
           
        
           
        
           
       
           
       
           
       
           
        
        
        
        
        
        
        
        
        
      
           
       
    
    
      
           
       
           
      
           
     
           
     
           
       
     
           
     
           
      
           
      
           
      
           
      
           
       
           
      
           
      
           
      
           
       
           
       
          
         buffering 
       
           
      
           
      
           
       
           
        
           
        
          
          Replay 
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
        
           
        
           
        
           
       
           
      
           
      
           
      
           
      
           
      
           
       
           
      
           
     
           
     
           
      
           
     
           
     
           
      
           
       
           
        
           
       
           
       
           
        
          
          LIVE 
        
           
        00:00 
         /  
        00:00 
       
           
       
           
        
           
        
           
        
           
         
           
         
           
         
           
         
           
         
           
         
           
        
           
        
           
        
           
       
           
       
           
        
           
        
          
          LIVE 
        
           
       
           
       
           
        
           
        
          
          CC 
        
           
       
           
       
           
        
           
       
           
       
           
       
           
        
           
        
           
         
           
        
           
       
           
       
           
        
           
       
           
      
           
      
           
       
           
        
           
        
           
         
           
         
           
         
           
          
           
          
           
          
           
         
           
        
           
       
           
      
           
      
           
       
           
     
       
           
    
       
           
       
    
  
       
           
   
       
           
       
       
           
      
           
      
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       Opacity : 
        
      
           
     
           
     
           
     
           
      
           
  
     
           
    
           
    
           
    
           
     
          
       Share: 
     
           
      
     
           
      
      Copy 
     
           
      
    
           
    
          
      Close 
      
    
           
    
           
      
    
           
    
           
   
           
  
           
  
           
    
    
    
   
           
   
           
 
    
   
           
   
           
   
           
    
           
     
           
      
           
       
           
        
           
          
          
         
          
          hotspot 

          
          
            
          
          

           
           
        
           
       
           
      
           
     
           
    
           
    
           
     
           
      
           
      
           

                       
          hotspot  
          
                                   
                 
                                      author：entertainment   
                                        
                                      
                                      -
 
browse：88
                                  
                                    
          
                                    
            
          
 
          Adam's take main illustration
          Molly Ferguson/STAT
          Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.
          Gilead needs Arcellx more than ever
          The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?
          advertisement
          If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
           
 
 
          

                              
          
                                 Previous article：

                                
                                          Guidelines to prevent youth baseball injuries need more muscle
                                
                            
          Next article：  
                                      
                                          Ebola public health emergency is over, WHO declares
                                                                    
          

      
           
      
           
        
           
                                               
        
           hotspot 
           
                   
      
           
  
  
          
    
          
        
          
            
          
                                                     
                
          focus
          
                            
          
        
          
        
    
          

          

    

      
           
     
           


   
    
           
   
           
  
 

  
           
    
           
           
           
            
            Back To Top 
           
           
           
           

            
           
                                                                    
                 
          Wikipedia
           
                                      
            
           
          
           
                                                          
             
          explore
           
                             
            
           
            
           

                                                         
             
          hotspot
           
               
              
            
           
            
           
                                                         
             
          entertainment
           
                             
      
           
 
     
           
     
           
      
          
              0:58LindsayLohanandBaderShammasattendaneventonNov.9,2022,inNewYork.BryanBedder/GettyImages,FILELinds
             
           
      
          
        © 2013-2023.Company name All rights reserved.Site Map 
         WSS-More Templates  
             Guangdong ICP39name